GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults - GSK ( NYSE:GSK )
Wednesday, GSK plc GSK released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of Arexvy ( Respiratory Syncytial Virus Vaccine ) when co-administered with Shingrix ( Zoster Vaccine ) .
| Ticker |
Sentiment |
Impact |
|
AGEN
|
Somewhat Bearish
|
23 %
|
|
GSK
|
Neutral
|
44 %
|
